Success Story: Over 1 Month for NIW Approval Without RFE under Premium Processing for Postdoctoral Research Fellow
Client’s Testimonial:
"Thank you again for all the hard work on successfully getting this first step done!”
On May 8th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Research Fellow in the Field of Orthopedic Biomechanics (Approval Notice).
General Field: Orthopedic Biomechanics
Position at the Time of Case Filing: Postdoctoral Research Fellow
Country of Origin: South Korea
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: May 8th, 2026
Processing Time: 1 month, 13 days (Premium Processing Requested)
Case Summary:
"Therefore, [Client]'s review service, as well as his many accomplishments that I have outlined throughout this letter, illustrate his recognition as an expert in the orthopedic biomechanics research community and confirm his versatility and fundamental expertise in the field."
The statement above is taken from one of three recommendation letters submitted as part of the EB-2 NIW (National Interest Waiver) petition for a holder of a Ph.D. and an M.S. in mechanical engineering from South Korea. Drawing on our extensive experience and a proven track record of over 32,000 successful cases, our expert team meticulously crafted a compelling petition on their behalf.
Client Background and Proposed Endeavor
As a postdoctoral research fellow in the field of orthopedic biomechanics, the client's proposed endeavor is to continue research on developing and applying biomechanical testing, tissue culture systems, and translational large animal models to advance the repair and regeneration of orthopedic soft tissues and improve therapies for joint injuries and osteoarthritis. Currently conducting this work as a postdoctoral research fellow, the client is creating testing platforms for cartilage repair materials and biological agents, evaluating injectable tissue scaffolds in large animal models, and studying collagen-based frameworks combined with blood products to promote regeneration in soft tissues.
National Significance of the Research
We emphasized that this research is of significant importance and has far-reaching implications for the United States. The client's work directly addresses a critical national healthcare burden by developing regenerative therapies that repair tissues rather than merely manage symptoms, ultimately reducing reliance on costly surgeries, decreasing hospital visits, and advancing the nation's competitiveness in biotechnology and regenerative medicine.
The research aligns with key federal health priorities and advances critical and emerging technology areas identified by the National Science and Technology Council, reinforcing the U.S. commitment to maintaining global leadership in biotechnology and health innovation.
Impressive Credentials and Achievements
To further strengthen the case, we highlighted exceptional credentials:
- Publications: An impressive portfolio of 5 peer-reviewed journal articles (3 of them first-authored) and 2 conference abstracts (1 of them first-authored).
- Citations: The work has been cited 21 times.
- Peer Review Service: The client has been invited to conduct a peer review and has completed at least 1 review to date.
- Competitive Funding: The research has been supported by major federal and professional funding sources, including the National Institutes of Health (NIH), the National Science Foundation (NSF), and the Arthroscopy Association of North America (AANA), affirming the significance and national importance of the work.
Case Outcome
Considering the exceptional strength of the accomplishments and the national importance of the proposed endeavor, we are delighted to share that this NIW petition was approved in over 1 month under premium processing without RFE, aided by the premium processing upgrade. The client's innovative work in developing translational research infrastructure for orthopedic soft tissue repair and regeneration, combined with demonstrated expertise across biochemical testing, tissue culture systems, and large animal models, positions this researcher to make transformative contributions to U.S. musculoskeletal healthcare and patient outcomes for years to come.